메뉴 건너뛰기




Volumn 9, Issue 9, 2011, Pages 678-680

Novel targets for triple-negative breast cancer

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GEMCITABINE; INIPARIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PROGESTERONE RECEPTOR;

EID: 80054680259     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note
Times cited : (3)

References (4)
  • 1
    • 78751610848 scopus 로고    scopus 로고
    • C. Iniparib plus chemotherapy in cetastatic triple-negative breast cancer
    • O'Shaughnessy J, Osborne C, Pippe JE, et al. C. Iniparib plus chemotherapy in cetastatic triple-negative breast cancer. N Engl J Med. 2011;364:205-214.
    • (2011) N Engl J Med , vol.364 , pp. 205-214
    • O'Shaughnessy, J.1    Osborne, C.2    Pippe, J.E.3
  • 2
    • 78649760941 scopus 로고    scopus 로고
    • The addition of cetuximab to cisplatin increases overall response rate and progression-free survival in metastatic triple- negative breast cancer: Results of a randomized phase II study (BALI-1)
    • Abstract 2740
    • Baselga J, Gomez P, Awada A, et al. The addition of cetuximab to cisplatin increases overall response rate and progression-free survival in metastatic triple- negative breast cancer: results of a randomized phase II study (BALI-1). Ann Oncol. 2010;21:viii96-viii121. Abstract 2740.
    • (2010) Ann Oncol , vol.21
    • Baselga, J.1    Gomez, P.2    Awada, A.3
  • 3
    • 79959524883 scopus 로고    scopus 로고
    • Directed therapy of subtypes of triple-negative breast cancer
    • Carey L. Directed therapy of subtypes of triple-negative breast cancer. Oncologist. 2011;16 Suppl 1:71-78.
    • (2011) Oncologist , vol.16 , Issue.SUPPL. 1 , pp. 71-78
    • Carey, L.1
  • 4
    • 79953772036 scopus 로고    scopus 로고
    • Lapatinib vs trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy: Primary efficacy endpoint analysis of the GEPARQUINTO Study (GBG 44)
    • December 10, San Anotonio, TX
    • Untch M, Loibl S, Bischoff J, et al. Lapatinib vs trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy: primary efficacy endpoint analysis of the GEPARQUINTO Study (GBG 44). Presented at the San Antonio Breast Cancer Symposium; December 10, 2010; San Anotonio, TX.
    • (2010) Presented At the San Antonio Breast Cancer Symposium
    • Untch, M.1    Loibl, S.2    Bischoff, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.